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Background: The survival impact of single-agent treatment with
docetaxel, the standard regimen for relapsed patients with non-small
cell lung cancer (NSCLC), remains modest. We conducted a ran-
domized phase II study to evaluate the efficacy and safety of the
combination of docetaxel and S-1 in the second-line setting.
Methods: Patients with relapse of NSCLC after first-line platinum-
based chemotherapy were randomly assigned to docetaxel alone (60
mg/m2, day 1, q3 weeks; arm A) or a combination of docetaxel (40
mg/m2, day 1, q3 weeks) and S-1 (80 mg/m2, days 1–15; arm B). The
primary end point was response rate, whereas secondary endpoints
included overall survival, progression-free survival, and toxicity.
Results: Between 2005 and 2008, a total of 60 patients were
enrolled in the study. The objective response rates were 20.7% and
16.1% in arms A and B, respectively (p  0.81). Progression-free
survival was comparable in the two arms (median: 3.7 versus 3.4
months, p  0.27), whereas overall survival time was longer in arm
A (22.9 versus 8.7 months, p  0.02). The major toxicity was
myelosuppression with grade 3 neutropenia in 89.7% of patients
versus 64.5% in arms A and B, respectively.
Conclusions: This study suggests that docetaxel monotherapy
should continue to be considered the standard for second-line
chemotherapy against NSCLC.
Key Words: Docetaxel, Non-small cell lung cancer, Second-line
chemotherapy, S-1.
(J Thorac Oncol. 2010;5: 1430–1434)
Lung cancer is the leading cause of cancer death worldwide.Non-small cell lung cancer (NSCLC) accounts for approxi-
mately 80% of all lung cancers, and most patients with NSCLC
present with advanced disease at the time of diagnosis. Plati-
num-based chemotherapy has become the mainstay of treatment
for patients with advanced NSCLC, because it is associated with
a modest prolongation of life span and improvement of quality
of life.1–3 However, these patients will ultimately experience
disease progression and might require second-line chemother-
apy. Thus far, therapeutic efficacy has been demonstrated for
several agents in second-line chemotherapy against advanced
NSCLC.4–7 Compared with best supportive care, docetaxel pro-
duced superior overall survival and significant improvement of
quality of life.4 Recent noninferiority studies also demonstrated that
therapeutic results with some novel agents were equivalent to those
with docetaxel in the second-line setting.6,7 However, the therapeu-
tic benefits of these agents remain modest, with median survival
times of approximately 8 months. Thus, it is necessary to improve
the efficacy of second-line treatment of advanced NSCLC.
S-1 is an oral anticancer agent comprised of tegafur,
5-chloro-2,4-dihydroxypyridine, and potassium oxonate, in a
molar ratio of 1:0.4:1, based on biochemical modulation of
5-fluorouracil.8 In a phase II trial of S-1 for advanced NSCLC
conducted in Japan, the response rate was 22%, and the
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median survival time was 10.2 months.9 There were no severe
or unexpected nonhematologic toxicities. In addition, there
were less severe hematologic adverse events, with incidences
of grade 3 and 4 toxicities of 7% for neutropenia, 2% for
anemia, and 2% for thrombocytopenia.
One theoretical strategy for improving the efficacy of
second-line treatment is to combine agents with different mech-
anisms of action and toxicity. We speculated that a combination
of docetaxel and S-1 might have stronger effects against NSCLC
than single-agent docetaxel for the following reasons: (1) do-
cetaxel and S-1 have exhibited synergistic effects in human
gastric and breast cancer xenograft models10–12; (2) the toxicity
profiles, in particular those of hematologic adverse events, of
these two agents do not overlap; (3) promising results for a
combination of docetaxel and oral fluoropyrimidine capecitabine
have been reported in the treatment of advanced NSCLC13,14;
and (4) superior survival with a combination of docetaxel and
capecitabine versus single-agent docetaxel was obtained in a
randomized trial conducted for anthracycline-pretreated patients
with advanced breast cancer.15
With this background, the Okayama Lung Cancer Study
Group (OLCSG) conducted a randomized phase II study to
compare the efficacy and safety of a combination of docetaxel
and S-1 with those of single-agent docetaxel in patients with
NSCLC previously treated with platinum-based chemotherapy.
PATIENTS AND METHODS
Eligibility Criteria
Patients aged 75 years or younger with a life expect-
ancy of at least 3 months and histologically and/or cytolog-
ically confirmed advanced NSCLC were eligible for the
study. In addition, all patients met the following inclusion
criteria: stage IIIB or IV disease, at least one target lesion,
one prior platinum-based chemotherapy regimen with the last
dose administered at least 4 weeks before entry, an Eastern
Cooperative Oncology Group performance status (PS) of 0 to
1, adequate bone marrow function (neutrophils 2000/mm3,
platelets 100,000/mm3, and hemoglobin 10.0 g/dl), he-
patic function (total bilirubin 1.5 mg/dl, aspartate amino-
transferase and alanine aminotransferase within 2.5 times the
upper normal limit), renal function (serum creatinine 1.5
mg/dl and calculated creatinine clearance level 60 ml/min
[Cockroft and Gault formula]), and pulmonary function (par-
tial pressure of arterial oxygen 60 Torr).
Patients were excluded from the study of they had radio-
graphic signs of interstitial pneumonia, serious or uncontrolled
concomitant systemic disorders, a concomitant malignancy,
symptomatic brain metastases, pleural and/or pericardial effu-
sion requiring treatment, previous treatment with fluoropyrimi-
dines including S-1, concomitant use of 5-fluorocytosine, phe-
nytoin, or warfarin potassium, which might pharmacologically
interfere with S-1, or were pregnant or breast feeding. Patients
who had undergone first-line docetaxel-containing regimens
were allowed to enter the study if they had achieved objective
responses to the first-line chemotherapy.
This study was conducted in compliance with the prin-
ciples of the Declaration of Helsinki, and the protocol was
approved by the local Institutional Review Boards. All pa-
tients gave written informed consent before study entry.
Treatment
Randomization was conducted by a registration office
(Aichi Cancer Center Research Institute) and was dynamically
balanced for PS, previous chemotherapy with docetaxel, and
institution. After balancing with respect to the treatment arms in
each stratum for each prognostic factor using a minimization
method, patients were randomly allocated to receive docetaxel
60 mg/m2 administered as a 1-hour intravenous infusion every 3
weeks (arm A) or docetaxel 40 mg/m2 on the same schedule
combined with S-1 administered orally at 40 mg/m2 twice a day
after meals between the evening of day 1 and the morning of day
15 (arm B) for a minimum of four courses if possible. The doses
of docetaxel and S-1 in this study were determined based on the
results of a phase I study conducted in Japanese patients with
advanced or recurrent gastric cancer.16 The actual dose of S-1
was selected as follows: in patients with body surface area
(BSA)1.25 m2, 40 mg twice a day; BSA1.25 m2 but1.5
m2, 50 mg twice a day; and BSA 1.5 m2, 60 mg twice a day.
Dexamethasone and/or 5-HT3 receptor antagonists were admin-
istered according to the treatment policy of each individual
institution. Reductions of dose of docetaxel (only in arm A) and
S-1 were specified per protocol, with a maximum of one dose
reduction allowed. In addition, in arm B, one dose increment of
docetaxel (50 mg/m2) was specified in the protocol.
Assessments of Toxicity and Response
Toxicity was assessed and scored during treatment and at
monthly visits thereafter according to the Common Terminology
Criteria for Adverse Events version 3.0 (Japan Clinical Oncol-
ogy Group/Japan Society of Clinical Oncology version).17 Tu-
mor response was measured and recorded using the Response
Evaluation Criteria in Solid Tumors (RECIST) guidelines ver-
sion 1.018 at every treatment course and at monthly visits
thereafter until disease progression. Confirmation of objective
responses was required after at least 4 weeks.
End Points and Statistical Considerations
The primary end point of this randomized phase II study
was objective response rate (ORR). Secondary end points in-
cluded progression-free survival (PFS), overall survival (OS),
and characterization of the toxicities of the two regimens. A total
of 56 patients were required with a power of 80% and a 5%
two-sided significance level for detection of an absolute 7%
increase in response rate in the combined treatment arm, com-
pared with the threshold value of 7% determined on the basis of
a previous report.4 Relative risk (RR) of ORRs and their 95%
confidence intervals (CIs) were estimated using a stratified Cox
regression model. Assuming that some dropouts would occur in
each arm, 60 patients were considered needed in this study. PFS
was defined as the period from the date of randomization to the
first date of disease progression or of death from any cause. OS
was defined as the period from the date of randomization to the
date of death from any cause. Comparisons of PFS and OS
between the arms were stratified by PS and previous docetaxel
chemotherapy. Time-to-event distributions were calculated us-
ing the method of Kaplan and Meier, and differences between
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these distributions were assessed using the stratified log-rank
test. Hazard ratios of PFS and OS between the arms were also
estimated using a stratified Cox regression model. The 2 test or
Fisher’s exact probability test was used to compare proportions
of categorical variables. P values less than 0.05 on two-tailed
analyses were considered significant. Safety data for all patients
receiving protocol treatment were tabulated and summarized
descriptively. Compliance with S-1 treatment was assessed by
comparing the amounts of prescribed and actually taken medi-
cation. Statistical analyses were performed using STATA ver-
sion 10 (College Station, TX).
RESULTS
Baseline Patient Characteristics
Between October 2005 and October 2008, a total of 60
Japanese patients with advanced NSCLC were enrolled at six
institutions. Of those, 29 and 31 patients were randomly as-
signed to arms A and B, respectively. All the patients were
evaluable for efficacy and safety, and the baseline characteristics
were well balanced across the two arms (Table 1). Median
off-treatment time since the last dose of first-line chemotherapy
was 4.2 months (range, 1–45 months) in arm A and 3.7 months
(range, 1–12 months) in arm B. Nine patients who had received
first-line docetaxel-containing chemotherapy were also included in
this study (six in arm A, three in arm B). These patients each had a
partial response (PR) to the first-line chemotherapy, which included
a doublet of cisplatin and docetaxel (n 8) or a triplet of cisplatin,
docetaxel, and irinotecan (n 1). In addition, activating mutations
for epidermal growth factor receptor (EGFR) in tumor were de-
tected in 6 of 21 patients examined (2 of 10 in armA, 4 of 11 in arm
B), although this information was obtained in the post hoc analysis.
Treatment Delivered
Thirty patients received at least four courses of as-
signed treatment (17 [58.6%] in arm A, 13 [41.9%] in arm B).
The median number of courses of chemotherapy administered
was 5 (range, 1–6) in arm A and 3 (range, 1–6) in arm B. Six
patients (two in arm A, four in arm B) were withdrawn from
protocol treatment because of adverse events, and two in arm
B refused further treatment before four courses had been
administered. In addition, nine patients (31.0%) had a reduc-
tion of dose of docetaxel in arm A and eight patients (25.8%)
had reduction of dose of S-1 in arm B. One patient had an
increase in dose of docetaxel in arm B. Compliance with S-1
was 92.7% over all treatment courses.
Efficacy Evaluation
Of the 60 patients entered in this randomized phase II
study, 11 had a confirmed PR as best response (Table 2). Six
of these patients received docetaxel alone (ORR, 20.7%; 95%
CI, 8.0–39.7%), whereas five patients received a combination
of docetaxel and S-1 (ORR, 16.1%; 95% CI, 5.5–33.7%). No
difference in response rate was found between the two arms
(RR, 1.18; 95% CI, 0.31–4.41; p 0.81). In addition, of nine
patients who had previously received docetaxel, one patient
each in the two arms achieved PR.
At the time of analysis, the median follow-up time for all
patients was 16.9 months (range, 2.4–39.5 months). Thirty-four
(57%) patients had died during the follow-up period, mostly as
a result of disease progression (n  32). Median PFS was 3.7
months (95% CI, 1.5–6.7 months) for patients assigned to arm
A and 3.4 months (95% CI, 1.9–4.7 months) for those assigned
to arm B (p  0.27, Figure 1). Median OS and 1-year survival
rate were 22.9 months and 73.8% versus 8.7 months and 33.5%
for arms A and B, respectively (p 0.02 for survival, Figure 2).
In addition, hazard ratios between the two arms were 0.73 (95%
CI, 0.40–1.31; p 0.29) for PFS and 0.42 (95% CI, 0.19–0.89;
p  0.02) for OS, respectively.
Safety Evaluation
Of the 60 patients entered in this study, 59 (98.3%)
experienced at least one adverse event. The Common Termi-
TABLE 1. Baseline Patient Characteristics by Treatment Arm
DOC
(n  29)
DOC  S-1
(n  31)
Median age (range) 63 (40–75) 63 (44–75)
Gender
Male 23 26
Female 6 5
ECOG performance status
0 12 10
1 17 21
Smoking history
Never-smoker 6 8
Ever-smoker 23 23
Previous treatment with DOC
Yes 6 3
No 23 28
Response to previous chemotherapy
Partial response 15 14
Stable disease 13 16
Progressive disease 1 1
Time since previous chemotherapy
3 mo 11 11
3 mo 18 20
Disease stage
III 6 10
IV 23 21
Histology
Adenocarcinoma 21 19
Squamous 4 9
Others 4 3
DOC, docetaxel; ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Objective Tumor Response
DOC (n  29)
DOC  S-1
(n  31)
Partial response 6 5
Stable disease 13 14
Progressive disease 9 11
Nonevaluable 1 1
Response rate (95%
confidence interval)
20.7% (8.0–39.7%)a 16.1% (5.5–33.7%)a
ap  0.81 as estimated using a stratified Cox regression model.
DOC, docetaxel.
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nology Criteria for Adverse Events grade 3 and 4 toxicities
exceeding 5% of patients are listed in Table 3. Leukocyto-
penia (62.1% versus 54.8%), neutropenia (89.7% versus
64.5%), and febrile neutropenia (13.8% versus 3.2%) were
more frequently observed in arm A, whereas anemia (0%
versus 6.5%) and liver dysfunction (0% versus 6.5%) were
more frequent in arm B. Low-grade oral mucositis and
diarrhea were more common in arm B (data not shown).
However, differences between the two arms in the incidence
of none of the toxicities were significant. In addition, three
patients (two in arm A, one in arm B) experienced pulmonary
embolism; one of these events resulted in death in arm A.
However, events were judged by the Data Safety Monitoring
Committee unlikely to be related to study treatment.
Poststudy Treatment
Thirty-nine patients received at least one form of chemo-
therapy as poststudy treatment (18 [62.1%] in arm A, 21
[67.7%] in arm B). Twenty-six patients received treatment with
EGFR tyrosine kinase inhibitor (EGFR TKI; 14 [48.3%] in arm
A, 12 [38.7%] in arm B). PR and stable disease (SD) were
observed in six and five patients versus two patients each in arms
A and B, respectively. In addition, nine patients (31.0%) in arm
A received subsequent single-agent S-1 or S-1–containing chemo-
therapy; PRwas observed in one patient and SD in four. No patients
in arm B received subsequent treatment with S-1.
DISCUSSION
In terms of ORR, the primary end point of this study, we
failed to demonstrate additional effect of S-1 to docetaxel in
second-line chemotherapy for patients with advanced NSCLC
(20.7% versus 16.1%, p 0.81). We initially assumed the ORR
of docetaxel to be approximately 7% based on a previous report
published in 2000.4 In contrast, and similar to our findings,
docetaxel monotherapy produced higher ORR in a recent Japa-
nese phase III study19 than in a previous Western study.4 This
difference in ORR might be due to ethnic differences between
the two studies and differences in criteria for assessment of
response. In contrast, the low ORR in the combination arm
compared with the single-agent docetaxel arm might have been
due to the reduced dose of docetaxel used in this study. Indeed,
two independent Japanese phase I studies of the combination of
docetaxel and S-1 reported that the approved dose of docetaxel
(60 mg/m2) in Japan20 could not be tolerated with the standard
dose of S-1 (80 mg/m2).16,21 This seems to be one difficulty with
concurrent administration of these agents.
Although ORR and PFS were comparable in the two
arms, OS in the single-agent arm was significantly longer than
that in the combination arm (22.9 versus 8.7 months, p 0.02).
The median OS demonstrated in the single-agent arm seems to
FIGURE 1. Progression-free survival by treatment arm.
FIGURE 2. Overall survival by treatment arm.
TABLE 3. CTCAE Grade 3 Adverse Events Exceeding 5% of Patients
DOC (n  29) DOC  S-I (n  31)
No. of Patients No. of Patients
Grade 3 Grade 4 Total % Grade 3 Grade 4 Total %
Leukocytopenia 15 3 18 62.1 16 1 17 54.8
Neutropenia 8 18 26 89.7 11 9 20 64.5
Anemia 0 0 0 0 2 0 2 6.5
Febrile neutropenia 4 0 4 13.8 1 0 1 3.2
Pulmonary embolism 0 2a 2 6.9 0 1 1 3.2
Liver dysfunction 0 0 0 0 1 1 2 6.5
aOne patient developed fatal pulmonary embolism (grade 5).
CTCAE, Common Terminology Criteria for Adverse Events version 3.0; DOC, docetaxel.
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 Randomized Phase II Study in Relapsed NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 1433
be extraordinarily prolonged compared with the results of pre-
vious studies (7.0–14.0 months).4,6,7,19 This difference between
OS and PFS is considered attributable to interactions resulting
from poststudy treatment. Patients assigned to the single-agent
docetaxel arm responded well to poststudy treatment with EGFR
TKI (42.9% [6 of 14] versus 16.7% [2 of 12] in the single-agent
and combination arms, respectively). In addition, it is quite
interesting that, in the single-agent arm, almost all patients who
obtained disease control (i.e., PR and SD) with poststudy treat-
ment with S-1 did not respond to poststudy treatment with
EGFR TKI (data not shown). Although it is difficult to under-
stand this curious result, patient population benefited from treat-
ment with S-1 might be different from those with EGFR TKI,
because activating EGFR mutation in tumor had been reported
to negatively influence the effect of adjuvant chemotherapy with
uracil-tegafur.22 These effects of poststudy treatment might have
biased postrecurrent survival in favor of the single-agent do-
cetaxel arm.
A recent meta-analysis demonstrated that combination
chemotherapy was more toxic than single-agent chemother-
apy in the second-line setting.23 However, the severity of
toxicity in the combination arm is considered tolerable and
comparable to that in the single-agent arm. In contrast,
toxicity profiles differed somewhat between the two arms,
although not to statistically significant extents. In addition,
the toxicity profile of the combination arm was quite similar
to those observed in a recent single-arm Japanese study.21,24
The difference in toxicity profiles between our study and the
meta-analysis seem to be attributable to the differences in
agents used in these studies.
Although we could not detect a clinically significant
advantage of the combination of docetaxel and S-1 in second-
line chemotherapy against NSCLC, it should be noted that
this randomized phase II study was conducted in exploratory
fashion in a small sample of patients. In addition, determina-
tion of mutations activating EGFR in tumor was not specified
in the protocol. It is therefore important to interpret the results
of this study with caution.
In conclusion, we did not find docetaxel in combination
with S-1 to be superior in efficacy for relapsed patients with
NSCLC, suggesting that docetaxel monotherapy should con-
tinue to be considered standard therapy in this setting. This
study also corroborates other study results indicating that
combination chemotherapy in the second-line and later set-
ting may be detrimental compared with single-agent therapy,
potentially because of increased toxicity limiting the amount
of treatment being able to be administered feasibly.23,25
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